The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA. 1,
BA. 2, and BA. 3. BA. 1 accounts for the initial surge and is being replaced by BA. 2, whereas …

The emergence of Omicron sublineages impacts the therapeutic efficacy of anti-severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) …

Summary Background Since early 2022, Omicron BA. 1 has been eclipsed by BA. 2, which
was in turn outcompeted by BA. 5, which displays enhanced antibody escape properties …

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …

On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. The …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …

Despite an overall improvement in neutralising antibody titres following mRNA booster
vaccination or an omicron breakthrough infection (appendix p 5), there was a significant loss …

Abstract With declining SARS-CoV-2-specific antibody titers and increasing numbers of
spike mutations, the ongoing emergence of Omicron subvariants causes serious challenges …